Nasdaq

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
Insurancenewsnet.com

Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test

SAN CARLOS, Calif., Dec. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination ...
Nasdaq

Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights

SAN CARLOS, Calif., June 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
Business Wire

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, ...
Seeking Alpha

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
Business Insider

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

SAN CARLOS, Calif., Sept. 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the largest non-invasive prenatal test (NIPT ...
Business Wire

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study ...
FierceBiotech

Natera launches lung DNA test for catching transplant rejections

Capturing the small pieces of DNA found circulating in the bloodstream has made headlines as the basis of liquid biopsy tests for cancer, but Natera aims to use the same technology for a diagnostic ...
Seeking Alpha

Natera: A Genetic Investment Worth Watching And Holding

Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...
Yahoo Finance

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.